Antibody Therapeutics, Inc.

DUBLIN--( BUSINESS WIRE )--The "Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024-2029" report has been added to ResearchAndMarkets.com's offering. This analysis provides detailed revenue forecasts for the global market of bio-CDMOs. The forecasts are categorized by market and segment, offering valuable insights into the industry. The analysis focuses on highlighting the potential growth opportunities for participants by considering trends, business models, and innovative strategies. By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more complex treatment modalities, including cell and gene therapy (CGT), nucleic acid therapy, ADC, and bispecific antibodies. Biopharmaceutical companies that focus on these treatments will strive for reduced durations for clinical development and a greater focus on cost-effectively producing drugs with lower costs of goods sold (COGS). Biologics contract development and manufacturing organizations (Bio-CDMOs) are actively framing manufacturing and supply chain strategies, with a specific emphasis on partnering with service providers to optimize the production process. The US Inflation Reduction Act (IRA) and the BIOSECURE Act have the potential to slow down drug innovation and the demand for CDMO services, leading to radical transformations in global outsourcing dynamics and CDMO strategies. Venture capitalists are assisting their pharmaceutical portfolios by internally restructuring and extending their cash reserves. CDMOs have experienced a consistent decrease in demand, especially for the initial phases of development. However, in late 2023 and 2024, there was a rise in M&A transactions, favorable conditions for biotech financing and valuation, and a stabilization of inflation and interest rates. Demand will resurge, particularly from emerging biopharma and early-stage development, by 2024. The market segments cover various aspects, such as product type, cell expression type, modality, and geographic region. Considering the end of the COVID-19 pandemic and the current global geopolitical issues, demand for outsourcing has decelerated. CDMOs are experiencing a decline in demand, particularly from small and emerging biopharmaceutical companies and those in the early stages of development. This analysis provides a comprehensive examination of future trends, covering the period between 2024 and 2029. It includes insights on capacity expansions, mergers, acquisitions, and the expansion of service offerings. The analysis also investigates the impact of strategic imperatives, growth drivers, restraints, revenue share estimates, and opportunities for bio-CDMOs. Growth Opportunity Universe in Bio-CDMO Expanding Drug Product Capabilites to Support Anti-obesity Drugs Providing End-to-end mRNA Services Indian Domestic Players Enhance Biologics Capabilities Key Topics Covered: Growth Environment - Transformation in the Bio-CDMO Sector Why is it Increasingly Difficult to Grow? The Strategic Imperative The Impact of the Top 3 Strategic Imperatives on the Bio-CDMO Industry Growth Environment - Ecosystem in Bio-CDMO Biologics Industry - Outlook Biologics Industry - Key Therapeutic Area Outlook Biologics Pipeline by Modality and Phase Biologics Industry - Market size and Growth Rate Forecast by Modality Global Trends Impacting the Bio-CDMO Industry Industry Trends Impacting the Bio-CDMO Industry Business Model - Shift from Fee-for-service to Value-based Risk-sharing Value-based Risk-sharing Business Model Scope of Analysis Segmentation Segmentation Competitive Environment Key Competitors Growth Generator Growth Metrics Growth Drivers Growth Restraints Forecast Considerations Forecast Framework - Bio-CDMO Market Sizing Forecast Methodology - Bio-CDMO Market Revenue Forecast Revenue Forecast by Product Type Revenue Forecast by Cell-culture Type Revenue Forecast by Region Revenue Forecast by Modality Revenue Forecast Analysis Revenue Forecast Analysis by Region Revenue Share Revenue Share Analysis Cell and Gene Therapy Growth Metrics Revenue Forecast Forecast Analysis Vaccines Growth Metrics Revenue Forecast Forecast Analysis Antibody Therapeutics Growth Metrics Revenue Forecast Forecast Analysis Proteins and Peptides Growth Metrics Revenue Forecast Forecast Analysis Best Practice Recognition in Bio-CDMO For more information about this report visit https://www.researchandmarkets.com/r/rd1y4e About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Agreement combines drug discovery and plant-based platform expertise to accelerate discovery and development of a new generation of biologics-based medicines for areas of high unmet need KBio secures rights to ZabBio’s current monoclonal antibody (mAb) pipeline and associated intellectual property as well as rights to future products LONDON and SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- KBio, a leading developer of new biological treatments derived from a plant-based production system, today announced that it has entered into a strategic partnership agreement with ZabBio to develop a new generation of mAbs, as well as advance the development of select assets within ZabBio’s current mAb pipeline. Patrick Doyle, CEO of KBio, commented, “This partnership allows us to expand and build on our successful track record of working with ZabBio over the past decade. Through this partnership, we will significantly increase our in-house research and development capabilities, combining our extensive expertise to discover and develop a new generation of biologics-based medicines for a broad range of high unmet needs. ZabBio’s remarkable ability to identify antibody candidates suitable for our unique plant-based platform will be integral to expanding our growing pipeline. Utilising our unique technology, we believe we could address some of today’s major challenges in protein drug development with a goal of significantly reducing the time and cost currently required.” Dr. Kevin Whaley, CEO of ZabBio, commented, “The ZabBio team is well-versed in KBio’s plant-based platform and the exciting potential of the antibody therapeutics derived from this unique technology. We are excited to join forces with the KBio discovery team in San Diego to continue to create and accelerate the development of novel mAb therapies. Together, we have the potential to make a positive health impact by expanding future availability of effective mAb treatments globally.” Under the terms of the agreement, KBio will have development rights to select assets within ZabBio’s current pipeline of antibody therapies and associated intellectual property – including a late-stage preclinical anti-fungal mAb – as well as future products discovered under the collaboration. Ends About KBioKBio aims to create a new generation of biologics using its plant-based platform that has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. It is focused on developing novel product candidates in two core areas: 1) antibody therapies for areas of high unmet need; and 2) pandemic preparedness and response using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms. KBio is comprised of KBio Holdings Limited, a UK-incorporated subsidiary of BAT, and its subsidiary, KBio Inc., which conducts its operations in the U.S. For more information, please visit www.kbio.com. About ZabBio, Inc.ZabBio, Inc. is a privately held company in San Diego, CA dedicated to developing monoclonal antibody-based products that address unmet needs in infectious diseases and reproductive health. For more information, please visit www.zabbio.com. Investor Contact: Shabnam BashirSolebury Strategic Communicationssbashir@soleburystrat.com Media Contacts: Julia DeutschSolebury Strategic Communications jdeutsch@soleburystrat.com Claire WisbeyBATClaire_brough@bat.com